The market for treating pulmonary arterial hypertension (PAH) was estimated at US$ 5.2 billion in 2020 and is anticipated to grow at a CAGR of 5.4% to reach US$ 13.5 billion by 2028. Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease characterized by high blood pressure in the pulmonary arteries, which can lead to right heart failure and ultimately death. PAH can affect people of all ages and is more common in women than men.
The PAH market is a relatively small market, with only a limited number of approved therapies. The market is dominated by drugs that act on the endothelin pathway, such as bosentan, ambrisentan, and macitentan. Other approved drugs include prostacyclin analogs (epoprostenol, treprostinil, and iloprost) and phosphodiesterase type 5 inhibitors (sildenafil and tadalafil). Despite the availability of these treatments, there is still an unmet need for new therapies that can improve outcomes for PAH patients. The market for PAH is expected to grow in the coming years due to an increase in disease awareness, a growing number of diagnosed cases, and the development of new therapies. However, the high cost of treatment and the small patient population may limit the growth of the market.
Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=7234
Key Takeaways from Market Study
- Global pulmonary arterial hypertension market to reach a valuation of US$ 4.44 Bn by 2028.
- Market in North America holds a share of 35%.
- Demand for endothelin receptor antagonists (ERAs) is expected to increase at a 5% CAGR over the forecast period.
Why is the U.S. market for pulmonary arterial hypertension expanding so quickly?
Over 200,000 hospital admissions in the US are due to pulmonary arterial hypertension each year. The expansion of the PAH market in the United States is being driven by the availability of board-certified physicians, an increase in hospital admissions associated with PAH, the commercialization of new PAH medications, and a promising pharmacological pipeline.
Additionally, it is anticipated that the U.S. PAH market will grow faster due to the increasing prevalence of this disease caused by heavy alcohol consumption, rapid adoption of a sedentary lifestyle, and rising smoking habits among people.
Winning Strategy
Various strategic efforts are being implemented by industry participants in order to expand their market share. Product development and launches, distribution network expansion, partnerships, and mergers and acquisitions are all examples of this. To obtain a competitive advantage and strengthen their industrial presence, companies invest extensively in the development and sale of highly innovative products.
Many pharmaceutical companies are attempting to enter the PAH market by releasing generic versions of pulmonary arterial hypertension medications. In the next years, this is expected to boost competition.
For instance,
- In November 2020, Viatris Inc. was formed by combining Mylan N.V. and Pfizer Inc.’s Upjohn Business. Viatris has a large portfolio of biosimilars, branded and sophisticated generics, and over-the-counter pharmaceuticals, including Revatio, a PAH medication.
Key Companies Profiled
- Gilead Sciences Inc.
- Pfizer, Inc.
- GlaxoSmithKline plc
- Novartis International AG
- Bayer HealthCare
- United Therapeutics Corp
Overall, the PAH market is expected to continue to grow in the coming years, driven by an increase in disease awareness and the development of new therapies. However, the high cost of treatment and the small patient population remain significant challenges for companies operating in this market.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global pulmonary arterial hypertension market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2028.
The study divulges essential insights on the market on the basis of drug class (prostacyclin & prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators), by pipeline analysis (early-stage drug candidates (phase I & phase II) and late-stage drug candidates (phase III & registration Phase)), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
